Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. Organic revenue growth supported by benefits from IDEXX execution drivers including continued solid new business gains and double-digit year-over-year global premium installed base growth. Delivers EPS of $2.80, an increase of 11% as reported and 12% on a comparable basis, supported by operating margin expansion of 110 basis points as reported and 100 basis points on a comparable basis. Adjusts 2024 revenue guidance to $3,865 million - $3,890 million, a reduction of $38 million or ~1% at midpoint, incorporating expectations fo

IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 third quarter results for Thursday, October 31, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2024 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the l

Achieves second quarter revenue growth of 6% as reported and 7% organic, supported by CAG Diagnostics recurring revenue growth of 6% as reported and 7% organic. Solid growth supported by continued benefits from IDEXX execution drivers, including record second quarter premium instrument placements and double-digit year-over-year global premium instrument installed base growth. Delivers EPS of $2.44, a decline of 9% as reported reflecting a $62 million, $0.56 per share discrete expense accrual related to an ongoing litigation matter. On a comparable basis, excluding this impact, EPS increased 15%. Updates 2024 revenue guidance to $3,885 million - $3,945 million, reflecting 6.2% -

IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, will now host its 2024 second quarter conference call and webcast at 9:00 am ET on Tuesday, August 6, 2024, to minimize conflicts with other industry earnings announcements. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2024 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live conference call, please dial

IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 second quarter results for Tuesday, August 6, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2024 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. EDT on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the

Achieves first quarter revenue growth of 7% as reported and organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic Solid growth supported by continued benefits from IDEXX execution drivers including double-digit year-over-year installed base growth across global premium instrument platforms Delivers EPS of $2.81, reflecting operating margin contraction of 10 basis points as reported and on a comparable basis including ~180 basis point negative impact from lapping a customer contract resolution payment in Q1 2023 Updates 2024 revenue guidance to $3,895 million - $3,965 million, reflecting 6.5% - 8.5% growth as reported and 7% - 9% organic, d

IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 first quarter results for Wednesday, May 1, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2024 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live

Achieves fourth quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 11% reported and 10% organic Solid growth supported by continued benefits from IDEXX execution drivers, including 11% year-over-year expansion of IDEXX's global premium instrument installed base Delivers fourth quarter EPS of $2.32, an increase of 13% as reported and 17% on a comparable basis Provides initial outlook for 2024 revenue of $3,930 million - $4,040 million, reflecting growth of 7.5% - 10.5% reported and 7% - 10% organic, supported by CAG Diagnostics recurring revenue growth of 7.5% - 10.5% as reported and on an organic basis Estimates 2024 EPS

IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 fourth quarter and full year financial results for Monday, February 5, 2024 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2023 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by teleph

Achieves third quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 10% reported and 9% organic Solid revenue growth reflects benefits from IDEXX execution drivers including double-digit year-over-year installed base growth across global premium instrument platforms Delivers EPS of $2.53, representing 18% growth as reported and 16% on a comparable basis, supported by operating margin expansion of 100 basis points as reported and 140 basis points on a comparable basis Adjusts 2023 revenue guidance to $3,635 million - $3,650 million, reflecting 7.9% - 8.4% growth as reported and 8.3% - 8.8% organically, driven by projected CAG D

SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

SC 13G - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

SC 13G - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

BTIG Research initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $580.00

Piper Sandler downgraded IDEXX Labs from Overweight to Neutral and set a new price target of $525.00

Exane BNP Paribas initiated coverage of IDEXX Labs with a rating of Outperform and set a new price target of $602.00

Cleveland Research upgraded IDEXX Labs from Neutral to Buy

Atlantic Equities downgraded IDEXX Labs from Overweight to Neutral and set a new price target of $610.00

Stifel downgraded IDEXX Labs from Buy to Hold and set a new price target of $415.00

Goldman upgraded IDEXX Labs from Neutral to Buy and set a new price target of $435.00 from $530.00 previously

Piper Sandler initiated coverage of IDEXX Labs with a rating of Overweight and set a new price target of $440.00

BofA Securities downgraded IDEXX Labs from Buy to Neutral and set a new price target of $470.00 from $550.00 previously

Atlantic Equities initiated coverage of IDEXX Laboratories with a rating of Overweight and set a new price target of $650.00

IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 20 years by 3.33% on an annualized basis producing an average annual return of 11.73%. Currently, IDEXX Laboratories has a market capitalization of $38.80 billion. Buying $100 In IDXX: If an investor had bought $100 of IDXX stock 20 years ago, it would be worth $939.70 today based on a price of $469.85 for IDXX at the time of writing. IDEXX Laboratories's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's au

In the current market session, IDEXX Laboratories Inc. (NASDAQ:IDXX) price is at $487.60, after a 0.87% increase. However, over the past month, the stock fell by 3.66%, and in the past year, by 9.18%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. Comparing IDEXX Laboratories P/E Against Its Peers The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the com

IDEXX Laboratories's (NYSE:IDXX) short percent of float has risen 17.34% since its last report. The company recently reported that it has 2.05 million shares sold short, which is 3.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.44 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short int

IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 10 years by 11.08% on an annualized basis producing an average annual return of 22.02%. Currently, IDEXX Laboratories has a market capitalization of $39.33 billion. Buying $100 In IDXX: If an investor had bought $100 of IDXX stock 10 years ago, it would be worth $726.72 today based on a price of $487.99 for IDXX at the time of writing. IDEXX Laboratories's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's a

Stifel analyst Jonathan Block maintains IDEXX Laboratories (NASDAQ:IDXX) with a Hold and lowers the price target from $520 to $510.

IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 10 years by 11.41% on an annualized basis producing an average annual return of 22.31%. Currently, IDEXX Laboratories has a market capitalization of $41.65 billion. Buying $1000 In IDXX: If an investor had bought $1000 of IDXX stock 10 years ago, it would be worth $7,592.67 today based on a price of $504.33 for IDXX at the time of writing. IDEXX Laboratories's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga

IDEXX Laboratories's (NYSE:IDXX) short percent of float has risen 3.44% since its last report. The company recently reported that it has 1.75 million shares sold short, which is 2.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.47 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short inte

IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 20 years by 2.72% on an annualized basis producing an average annual return of 10.59%. Currently, IDEXX Laboratories has a market capitalization of $41.16 billion. Buying $1000 In IDXX: If an investor had bought $1000 of IDXX stock 20 years ago, it would be worth $7,450.57 today based on a price of $498.35 for IDXX at the time of writing. IDEXX Laboratories's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga'

IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 15 years by 11.59% on an annualized basis producing an average annual return of 24.04%. Currently, IDEXX Laboratories has a market capitalization of $44.88 billion. Buying $100 In IDXX: If an investor had bought $100 of IDXX stock 15 years ago, it would be worth $2,531.73 today based on a price of $543.45 for IDXX at the time of writing. IDEXX Laboratories's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's

BRADENTON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ:FWRG) ("First Watch" or the "Company"), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Irene Chang Britt to its Board of Directors, effective immediately. Ms. Chang Britt is an experienced independent board director and former Fortune 500 C-suite executive, who currently serves on the boards of established businesses and start-up companies representing a variety of industries, including retail, CPG, e-commerce and lifestyle. "We are thrilled to welcome Irene to the Board of Directors of First Watch, and I'm confident that our company wil

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company's Board of Directors effective September 20, 2021. "We are excited to welcome Merilee to our Board of Directors," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "Merilee brings a wealth of operational, financial, and business experience to our team. Having started as employee #11 at IDEXX, she helped to drive a multitude of innovative growth strategies and successfully scaled the business from sta